Indonesia Energy Corporation Limited vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Indonesia Energy Corporation Limited trades at $2.85 (market cap $43.24M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 584.4× Indonesia Energy Corporation Limited's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| INDO | RPRX | |
|---|---|---|
Market Cap | $43.24M | $25.27B |
Volume | 116,953 | 3,671,183 |
Sector | Energy | Health |
52-Week High | $6.74 | $63.96 |
52-Week Low | $2.49 | $35.44 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $38.18M | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.77, unchanged on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $5.10 million in 2025 on revenue of $2.01 million, reflecting negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite a 100% buy rating from 3 analysts, INDO faces significant financial challenges with negative profitability and cash burn. Investment potential hinges on successful execution of drilling operations to boost revenue, but risks include sustained losses, high valuation multiples relative to sales, and reliance on financing activities.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →